OVID · Ovid Therapeutics Inc. · Metrics
$2.33
-0.05 (-2.10%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$468.71M
Shares
195.30M
Volume · Oct 5
573.69K
Avg daily vol (3M)
1.63M
OVID metrics
62 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$2.38
Market cap
$468.71M
Price action
20 metricsPrice change (1W)
-0.8%
Price change (30D)
-13.5%
Price change (3M)
-11.5%
Price change (6M)
+8.2%
Price change (YTD)
+46.0%
Price change (1Y)
+45.1%
Trailing year
Price change (5Y)
-32.6%
52-week high
$2.96
52-week low
$1.20
Change from 52-week high
-19.6%
Change from 52-week low
+98.3%
Annualized volatility
77.7%
Annualized volatility (3M)
51.4%
Beta
1.2
RSI (14D)
36.7
Price vs SMA 50
-9.8%
Price vs SMA 200
+3.7%
Avg volume (3M)
1.63M
Relative volume
1.3
Average dollar volume
$4.28M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
195.30M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
296.1×
reciprocal yield 0.3%
P / book
2.2
reciprocal yield 44.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.4%
Historical valuation
8 metricsP / E historical average (3Y)
2.0×
reciprocal yield 49.1%
P / E historical average (5Y)
2.0×
reciprocal yield 49.1%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-03-18
Profitability
9 metricsGross margin
—
Operating margin
-3,686.7%
Trailing 12 months
Net margin
-2,178.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$58.36M
Net income (TTM)
−$34.49M
Trailing 12 months
Diluted EPS (TTM)
$-0.46
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-88.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.58M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.5%
Year over year · more shares
Revenue CAGR (3Y)
+69.0%
Revenue CAGR (5Y)
-10.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-16.4%
Return on assets
-14.9%
Debt / equity
—
Current ratio
12.4
EBITDA (TTM)
−$58.28M
Free cash flow (TTM)
—
Quick ratio
12.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$11.33M
Latest balance sheet
Cash & equivalents
$11.33M
Total assets
$231.97M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$54.77M
Capital expenditures (TTM)
$0
R&D (TTM)
$33.60M
SG&A (TTM)
—
Stock compensation (TTM)
$4.78M
R&D / revenue
2,122.3%
Stock compensation / revenue
302.0%
Ownership (13F)
3 metrics13F filers
131
13F filer change QoQ
+28
Institutional ownership
75.4%
Short interest
3 metricsShort interest
10.8%
Latest settlement · 17.3 days to cover
Days to cover
17.3d
Short-squeeze score
79 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—